JENNER VACCINE FOUNDATION

Legal registered address
C/O Jenner Institute Old Road Campus Research Building Roosevelt Drive Oxford England OX3 7DQ Copied!

Latest financial results as of 31 August 2025
Cash in bank
£35.67k
Current assets
£40.33k
Fixed assets
£523.73k
Current creditors
£25.29k
Shareholders funds
£651.67k
View full financial accounts

Company number
03079818 Copied!
Company status
Active
Company type
PRI/LBG/NSC (Private, Limited by guarantee, no share capital, use of 'Limited' exemption)
Accounts category
Full
Incorporated on
14 July 1995
Accounts

Latest annual accounts were to 31 March 2024

Next annual accounts are due by 30 April 2026

Company financial year end is on 31 July 2026

Confirmation statement

Latest confirmation statement statement dated 30 June 2025

Next statement due by 14 July 2026

View original and historic source data
Nature of business (SIC)

72200 - Research and experimental development on social sciences and humanities

Previous company names

NameDate previous name changed
THE EDWARD JENNER INSTITUTE FOR VACCINE RESEARCH12 October 2006

Latest company documents
DateDescription
06/02/256 February 2025 Register(s) moved to registered inspection location Finance Division, University of Oxford C/O Oxford University Press Great Clarendon Street Oxford OX2 6DP

View Document

05/02/255 February 2025 Current accounting period extended from 2025-03-31 to 2025-07-31

View Document

18/12/2418 December 2024 Register inspection address has been changed to Finance Division, University of Oxford C/O Oxford University Press Great Clarendon Street Oxford OX2 6DP

View Document

04/10/244 October 2024 Full accounts made up to 2024-03-31

View Document

12/07/2412 July 2024 Confirmation statement made on 2024-06-30 with no updates

View Document

View all company documents

More Company Information


Follow Company
  • Receive an alert email on changes to financial status
  • Early indications of liquidity problems
  • Warns when company reporting is overdue
  • Free service, no spam emails
  • Follow this company